RE:RE:RE:RE:RE:Companies now seek to moderate TME to expand PD-(L)1 effectYes - over expression of CEACAM6 negatively modulates the TME in pancreatic cancer.
In order to avoid the immune response, tumor cells can change the degree of expression of specific antigens on the cell surface with the main objective to repress the activation of immune cells that would otherwise recognize and attack the transformed cells. One of those membrane proteins is the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family.
And as a resut CECAM6 has been described as a modulator of cancer progression for a number of reasons, and indeed, CEACAM6 is upregulated preferentially on the membranes of many tumors, including pancreatic cancer.
In an effort to lower its expression levels CEACAM6 has been used to create antibody–drug conjugates (ADC), using monocolonal antibody inhibitor as a payload, which has shown preclinical efficacy in pancreatic cancer.